Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My crystal ball tells me there's a company press release coming soon that will announce ELTP's presentation date/time for the R&R Conference. Look for favorable Phase III results to be announced either in the press release or just before/during ELTP's presentation at R&R conference. IMHO
Just a little over two weeks until the Rodman & Renshaw 17th Annual Global Investment Conference where ELTP will be presenting. It sure would be an opportune time for Nasrat to announce successful ELI-200 Phase III results to the World.
Here's the schedule for Rodman & Renshaw 17th Annual Global Investment Conference:
http://www.meetmax.com/sched/event_30869/~public/conference_agenda.html?event_id=30869
The presenting company names for particular dates/time slots haven't been provided yet. Despite having reached their full capacity of presenting companies, they are still taking registrants in the event of cancellations.
Webcasting of the Rodman & Renshaw Conference will be provided to presenting companies who elect to pay the additional fee for the optional service, which Elite did at last year's Conference.
http://www.prnewswire.com/news-releases/rodman--renshaw-2015-annual-global-investment-conference-to-be-held-in-new-york-from-september-8-to-10-2015-300110562.html
NEW YORK, July 9, 2015 /PRNewswire/ -- Rodman & Renshaw Conferences, LLC is hosting The Rodman & Renshaw Annual Global Investment Conference on September 8 through September 10, 2015 at the St. Regis Hotel in New York. More than 200 public & private companies from around the world are expected to present to an audience of over 2,000 attendees. The event will feature tracks devoted to Biotechnology/Healthcare, Metals & Mining, Technology, Cleantech and Growth. The Conference will include corporate presentations and Q&A sessions, investor one-on-one meetings and daily networking opportunities. Institutional investors, venture capitalists, private equity firms, sophisticated private investors and industry executives are welcome to attend this conference. Register online at the Rodman & Renshaw Conference website at www.rodmanevents.com or contact Lily Khaykina, Rodman & Renshaw's Conference Manager, at (212) 356-0529 or via e-mail at LK@rodmanevents.com
Presenting Companies (partial list)
Elite Pharmaceuticals, Inc. (OTCQB: ELTP)
JJ,
I agree with you on all your points. Nasrat's full attention and resources are focused on getting ELI-200 to market and getting 2 or 3 more ADFs into the pipeline. His goal is to grow ELTP organically in order to up-list on NASDAQ and/or garner an acceptable buyout offer. As you stated, it takes alot of cash to bring several drugs to market. That was the reason for the Novel sale, ELI-200 agreement with Epic and tapping into LPC again. It's the old adage... It takes money to make money. In the end, ELTP and its shareholders will reap huge rewards, IMHO.
GLTY
MJ
Gman,
Kudos really should go to fellow iHub board member, "snupoled", who mailed the question list to ELPT's Investor Relations. I sent an e-mail this evening to Diane thanking her for getting the list to Nasrat and for his participation. I also told her that it would be beneficial and greatly appreciated by ELTP shareholders if the practice could continue for future Conference Calls.
Kudos are also due to those who submitted questions to the list. Couldn't have done it without their contributions.
MJ
I met ELTP's Board Members from Epic at last year's Shareholder's meeting. One remarked to me that Nasrat Hakim taking over the helm of ELTP was a game changer. So they have the utmost confidence in him to put Epic's money on the line.
Record breaking 10Q and great CC. Lots of eyes are on ELTP... There were also so many callers that I got shutout of the Q&A session for the first time. Despite missing out, I was very pleased that Nasrat addressed many of the questions taken from our Q&A list. I'm already looking forward to the Annual Shareholders Meeting.
**** Elite Pharmaceuticals Conference Call Questions ****
Those participating in ELTP’s Conference Call Q&A session are limited to asking one question following ELTP management’s opening statements. To make the most of this Q&A opportunity, suggest that we come up with a list to share of top questions to ask:
(Copy/paste the latest posted list and add your question(s) at the end of the list)
1. Any plans for ELI-154?
2. Updates on ELI-201 and ELI-202?
3. Update on ELI-202 BE?
4. Any generics moving up the ladder to commercialization?
5. Elite had an agreement with Epic for 8 drugs where Elite gets a 15% profit split. Elite is no longer proceeding with the last 7 drugs. However, the first and only drug has been filed with the FDA for 3 1/2 years now and we haven't heard anything. Do you have any updates on this?
6. Are there any numbers yet on the sales of Isradpin?
7. Status update on the arbitration of Phentermine with Precision Dose?
8. Given Elite's generic NDA ART line takes less time and money to bring to market than Elite's once daily Eli 216 product, what are the current plans for this product? How likely is it to partner a combo Eli 201 and 216 together? How quickly are you planning to move forward with this product since there is no other once daily abuse resistant product on the market?
9. What is the up to date information on the Public Float and Shares Outstanding for ELTP?
10. Given Nasrat's experience working at Alpharma and Actavis... Does he think Elite's patents are different enough from Purdue not to move toward legal avenues? If not, does Nasrat believe royalties fees would be the end result for Elite?
11. How does Elite's ADT compare to other ADT products that purport to detour swalling a handful of pills? What would it take to get Elite to attach "similar" ADT. How does Elite's microtablet technology improve on Elite's existing ADT? What is the microtablet technology worth once Elite begins to market its ADT opioids?
12. Will Elite get only $15 million for ELI-200? What percentage of the royalties does Elite get? What exactly will the royalties consist of? What will the royalty be on the net product sales??
13. Did Epic ever settle with Purdue?
14. Does Epic have right of first refusal on future opioid ART drugs that are approved or is ELI-200 a one shot deal with plans
to bring in bigger game?
15. Does Epic have plans to ramp up sales and marketing departments in anticipation of marketing ELI-200 or future ART drugs?
16. What are the chances of an Epic and Elite merger? What would a reverse merger do to the PPS?
17. What's the current status of Mikah and the relation between Mikah/Epic as well as any possible conflict of interest that relation can cause to Elite?
18. Will there be a new valuation/assessment?
19. Will there be any Pie Charts to show shareholders the increase in shares?
20. We seem to have been "flying under the radar" for quite awhile now. Does Nasrat plan on presenting at more conferences (Rodman and Renshaw and others) to promote awareness and interest in the company now that we are in the last stretch for ELI 200?
21. Since EPIC is going to be marketing its own ER ADT OXY and Elite's IR ADT OXY at the same time, which ADT will Epic be using.....Will it be a hard turtle shell version like Purdue/Actavis has agreed upon.......OR is EPIC going to be using a version of Elite's ADT?
22. What are the scenarios/circumstances that would engage Elite to pursue up listing to the Nasdaq or anything comparable?
23. The annual shareholders meeting- when? There has been speculation that it's "pushed-back" timing may coincide with some expected big news/results/announcements?
24. What is the rational/need for issuing additional shares to Lincoln Park in light of the revenue that will be gained from the recent licensing agreement with Epic? If the goal is to uplist to Nasdaq, doesn't the continued issuance of shares impede this goal?
25. Status update on the new fluid bed dryer.
**** Elite Pharmaceuticals Conference Call Questions ****
Those participating in ELTP’s Conference Call Q&A session are limited to asking one question following ELTP management’s opening statements. To make the most of this Q&A opportunity, suggest that we come up with a list to share of top questions to ask:
(Copy/paste the latest posted list and add your question(s) at the end of the list)
1. Any plans for ELI-154?
2. Updates on ELI-201 and ELI-202?
3. Update on ELI-202 BE?
4. Any generics moving up the ladder to commercialization?
5. Elite had an agreement with Epic for 8 drugs where Elite gets a 15% profit split. Elite is no longer proceeding with the last 7 drugs. However, the first and only drug has been filed with the FDA for 3 1/2 years now and we haven't heard anything. Do you have any updates on this?
6. Are there any numbers yet on the sales of Isradpin?
7. Status update on the arbitration of Phentermine with Precision Dose?
8. Given Elite's generic NDA ART line takes less time and money to bring to market than Elite's once daily Eli 216 product, what are the current plans for this product? How likely is it to partner a combo Eli 201 and 216 together? How quickly are you planning to move forward with this product since there is no other once daily abuse resistant product on the market?
9. What is the up to date information on the Public Float and Shares Outstanding for ELTP?
10. Given Nasrat's experience working at Alpharma and Actavis... Does he think Elite's patents are different enough from Purdue not to move toward legal avenues? If not, does Nasrat believe royalties fees would be the end result for Elite?
11. How does Elite's ADT compare to other ADT products that purport to detour swalling a handful of pills? What would it take to get Elite to attach "similar" ADT. How does Elite's microtablet technology improve on Elite's existing ADT? What is the microtablet technology worth once Elite begins to market its ADT opioids?
12. Will Elite get only $15 million for ELI-200? What percentage of the royalties does Elite get? What exactly will the royalties consist of? What will the royalty be on the net product sales??
13. Did Epic ever settle with Purdue?
14. Does Epic have right of first refusal on future opioid ART drugs that are approved or is ELI-200 a one shot deal with plans
to bring in bigger game?
15. Does Epic have plans to ramp up sales and marketing departments in anticipation of marketing ELI-200 or future ART drugs?
16. What are the chances of an Epic and Elite merger? What would a reverse merger do to the PPS?
17. What's the current status of Mikah and the relation between Mikah/Epic as well as any possible conflict of interest that relation can cause to Elite?
18. Will there be a new valuation/assessment?
19. Will there be any Pie Charts to show shareholders the increase in shares?
20. We seem to have been "flying under the radar" for quite awhile now. Does Nasrat plan on presenting at more conferences (Rodman and Renshaw and others) to promote awareness and interest in the company now that we are in the last stretch for ELI 200?
21. Since EPIC is going to be marketing its own ER ADT OXY and Elite's IR ADT OXY at the same time, which ADT will Epic be using.....Will it be a hard turtle shell version like Purdue/Actavis has agreed upon.......OR is EPIC going to be using a version of Elite's ADT?
22. What are the scenarios/circumstances that would engage Elite to pursue up listing to the Nasdaq or anything comparable?
23. The annual shareholders meeting- when? There has been speculation that it's "pushed-back" timing may coincide with some expected big news/results/announcements?
24. What is the rational/need for issuing additional shares to Lincoln Park in light of the revenue that will be gained from the recent licensing agreement with Epic? If the goal is to uplist to Nasdaq, doesn't the continued issuance of shares impede this goal?
ELTP's 10Q is out ( http://ir.elitepharma.com/sec_filings ). Should conjure up questions for tomorrow's CC. Be sure to add them to the Q&A List:
**** Elite Pharmaceuticals Conference Call Questions ****
Those participating in ELTP’s Conference Call Q&A session are limited to asking one question following ELTP management’s opening statements. To make the most of this Q&A opportunity, suggest that we come up with a list to share of top questions to ask:
(Copy/paste the latest posted list and add your question(s) at the end of the list)
1. Any plans for ELI-154?
2. Updates on ELI-201 and ELI-202?
3. Update on ELI-202 BE?
4. Any generics moving up the ladder to commercialization?
5. Elite had an agreement with Epic for 8 drugs where Elite gets a 15% profit split. Elite is no longer proceeding with the last 7 drugs. However, the first and only drug has been filed with the FDA for 3 1/2 years now and we haven't heard anything. Do you have any updates on this?
6. Are there any numbers yet on the sales of Isradpin?
7. Status update on the arbitration of Phentermine with Precision Dose?
8. Given Elite's generic NDA ART line takes less time and money to bring to market than Elite's once daily Eli 216 product, what are the current plans for this product? How likely is it to partner a combo Eli 201 and 216 together? How quickly are you planning to move forward with this product since there is no other once daily abuse resistant product on the market?
9. What is the up to date information on the Public Float and Shares Outstanding for ELTP?
10. Given Nasrat's experience working at Alpharma and Actavis... Does he think Elite's patents are different enough from Purdue not to move toward legal avenues? If not, does Nasrat believe royalties fees would be the end result for Elite?
11. How does Elite's ADT compare to other ADT products that purport to detour swalling a handful of pills? What would it take to get Elite to attach "similar" ADT. How does Elite's microtablet technology improve on Elite's existing ADT? What is the microtablet technology worth once Elite begins to market its ADT opioids?
12. Will Elite get only $15 million for ELI-200? What percentage of the royalties does Elite get? What exactly will the royalties consist of? What will the royalty be on the net product sales??
13. Did Epic ever settle with Purdue?
14. Does Epic have right of first refusal on future opioid ART drugs that are approved or is ELI-200 a one shot deal with plans
to bring in bigger game?
15. Does Epic have plans to ramp up sales and marketing departments in anticipation of marketing ELI-200 or future ART drugs?
16. What are the chances of an Epic and Elite merger? What would a reverse merger do to the PPS?
17. What's the current status of Mikah and the relation between Mikah/Epic as well as any possible conflict of interest that relation can cause to Elite?
18. Will there be a new valuation/assessment?
19. Will there be any Pie Charts to show shareholders the increase in shares?
20. We seem to have been "flying under the radar" for quite awhile now. Does Nasrat plan on presenting at more conferences (Rodman and Renshaw and others) to promote awareness and interest in the company now that we are in the last stretch for ELI 200?
21. Since EPIC is going to be marketing its own ER ADT OXY and Elite's IR ADT OXY at the same time, which ADT will Epic be using.....Will it be a hard turtle shell version like Purdue/Actavis has agreed upon.......OR is EPIC going to be using a version of Elite's ADT?
22. What are the scenarios/circumstances that would engage Elite to pursue up listing to the Nasdaq or anything comparable?
23. The annual shareholders meeting- when? There has been speculation that it's "pushed-back" timing may coincide with some expected big news/results/announcements?
10Q is published:
http://ir.elitepharma.com/sec_filings
Elite Pharmaceuticals, Inc. Reports Record Revenues for First Quarter of Fiscal Year 2016
Webcast and Conference Call Scheduled for Tuesday, August 11th at 11:00 AM EDT
NORTHVALE, N.J., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), announced results for the quarter ended June 30, 2015, the first quarter of its 2016 fiscal year.
Consolidated revenues for the first quarter of Fiscal 2016 were $7.1 million, with operating profits totaling $2.5 million. Revenues consisted of $5 million in milestone payments from the ELI-200 license to Epic Pharma and a record $2.1 million generated from product revenue. The milestone payments are the first of a total $15 million in milestones from the ELI-200 licensing agreement. The license agreement also includes, upon commercialization, royalty payments based on net sales. Elite invested $2.4 million this quarter in clinical trials for ELI-200 and on other product development activities, and net income was $16.1 million. Elite will provide an update on development activities during the conference call.
"I am extremely pleased with the record revenues and operating profit this quarter," commented Nasrat Hakim President and CEO of Elite. "I am also excited that Elite has completed dosing of the efficacy study required for the ELI-200 submission. We will have final results for this trial later this year and we expect to complete our NDA submission for ELI-200 thereafter."
Conference Call Information
Elite's management will host a conference call to discuss the results of operations and provide an update on recent business developments: Company executives will conduct a question and answer session following their remarks.
Date: Tuesday, August 11, 2015
Time: 11:00 a.m. EDT
Webcast (live and archive) & Audio Replay: http://ir.elitepharma.com/events_presentations
Dial-in numbers: 800-346-7359 (domestic)
973-528-0008 (international)
Conference number: 98840
Access to ELTP webpage is very slow... I suspect they are publishing the news release now...
ELTP's first quarter financial results will be released tomorrow. Should be another outstanding quarter on the books. Looking forward to Tuesday's CC.
I agree... Could be a very interesting CC given that this is ELTP's first time doing a webcast.
That's my interpretation, too... Yet here's another question/answer from the same SEC document that implies a webcast is sufficient public disclosure:
Question 102.05
Question: Can an issuer satisfy Regulation FD's public disclosure requirement by disclosing material nonpublic information in a speech at a shareholder meeting open to the public? The meeting will not be covered by the press, or webcast or broadcast by any electronic means.
Answer: No. Under Rule 101(e), public disclosure of information required to be disclosed by Rule 100(a) can be made either by furnishing or filing with the Commission a Form 8-K disclosing that information, or by disseminating the information through another method or combination of methods of disclosure "that is reasonably designed to provide broad, non-exclusionary distribution of the information to the public." A meeting that is open to the public but not otherwise webcast or broadcast by any electronic means is not a method of disclosure "reasonably designed to provide broad, non-exclusionary distribution of the information to the public." [Aug. 14, 2009]
SEC Regulation FD
https://www.sec.gov/divisions/corpfin/guidance/regfd-interp.htm
Section 102. Rule 101: Definitions
Question 102.01
Question: If an issuer wants to make public disclosure of material nonpublic information under Regulation FD by means of a conference call, what information must the issuer provide in the notice and how far in advance should notice be given?
Answer: An adequate advance notice under Regulation FD must include the date, time, subject matter and call-in information for the conference call. Issuers also should consider the following non-exclusive factors in determining what constitutes adequate advance notice of a conference call:
Timing: Public notice should be provided a reasonable period of time ahead of the conference call. For example, for a quarterly earnings announcement that the issuer makes on a regular basis, notice of several days would be reasonable. We recognize, however, that the period of notice may be shorter when unexpected events occur and the information is critical or time sensitive.
Availability: If a transcript or re-play of the conference call will be available after it has occurred, for instance via the issuer's website, we encourage issuers to indicate in the notice how, and for how long, such a record will be available to the public. [Aug. 14, 2009]
Snup,
I apologize if my posts offended you... That certainly isn't my intent. There's no doubt that we both want ELTP to succeed. I'm confident that Nasrat has the right stuff to get it done. I look forward to celebrating ELTP's success with all my fellow shareholders one day. The first round is on me.
MJ
I've been thinking about the newly featured Webcast for this CC, too. This greatly expands the reach for more participation and also brings a video capability to the meeting that we haven't had before. Who knows... Maybe we'll see Nasrat lighting up a cigar with a $100 bill after announcing another ELTP record quarter.
Snup...
I'm no insider... I've done my DD and have been a ELTP shareholder for several years, never selling a single share. I participate in all the CC's and made the 250 mile drive to last year's Annual Shareholders meeting to see Nasrat and ELTP's Board members in person.
Guess I'm just failing to see what/why you are so dissatisfied with Nasrat. To say that his credibility is on the line at next Tuesday's CC is a bit of an exaggeration given the fact that ELI-200 is on the cusp of getting FDA approval to file. That is the prize I'm keeping my eye on... All else is just noise.
MJ
Snup,
I'm happy if Nasrat is putting all his attention and ELTP's resources on getting the FDA's approval for ELI-200 to file. Bringing it to market is the game changer for ELTP. Nasrat is making steady progress. But with what's at stake, he is also being cautious to insure nothing jeopardizes ELTP achieving the ultimate goal. Nasrat is not the only factor... ELI-200's fate ultimately rests in the hands of the FDA. They control the clock... Not Nasrat.
MJ
I usually rank what I feel to be the best questions from the list. Then when my turn comes, I'll ask the top question whether it's mine or not. Just ask Couch... I "steal" his all the time. The important thing is to get most, if not all, the best questions asked in the allotted time.
Snup,
I'm not opposed to sending an advance copy of the Q&A list to IR. But there has been opposition expressed here in the past about doing so... Some feel it would lead to canned/prepared answers. If a list is sent to IR, I would recommend it be limited to the top 10 questions. Now arriving at a consensus as to what those are is the challenge.
MJ
ELTP's 1st quarter financial results come out on August 10th, followed by a Conference Call on August 11th. Get your questions added to the list, call-in next Tuesday and participate in the Q&A session!
**** Elite Pharmaceuticals Conference Call Questions ****
Those participating in ELTP’s Conference Call Q&A session are limited to asking one question following ELTP management’s opening statements. To make the most of this Q&A opportunity, suggest that we come up with a list to share of top questions to ask:
(Copy/paste the latest posted list and add your question(s) at the end of the list)
1. Any plans for ELI-154?
2. Updates on ELI-201 and ELI-202?
3. Update on ELI-202 BE?
4. Any generics moving up the ladder to commercialization?
5. Elite had an agreement with Epic for 8 drugs where Elite gets a 15% profit split. Elite is no longer proceeding with the last 7 drugs. However, the first and only drug has been filed with the FDA for 3 1/2 years now and we haven't heard anything. Do you have any updates on this?
6. Are there any numbers yet on the sales of Isradpin?
7. Status update on the arbitration of Phentermine with Precision Dose?
8. Given Elite's generic NDA ART line takes less time and money to bring to market than Elite's once daily Eli 216 product, what are the current plans for this product? How likely is it to partner a combo Eli 201 and 216 together? How quickly are you planning to move forward with this product since there is no other once daily abuse resistant product on the market?
9. What is the up to date information on the Public Float and Shares Outstanding for ELTP?
10. Given Nasrat's experience working at Alpharma and Actavis... Does he think Elite's patents are different enough from Purdue not to move toward legal avenues? If not, does Nasrat believe royalties fees would be the end result for Elite?
11. How does Elite's ADT compare to other ADT products that purport to detour swalling a handful of pills? What would it take to get Elite to attach "similar" ADT. How does Elite's microtablet technology improve on Elite's existing ADT? What is the microtablet technology worth once Elite begins to market its ADT opioids?
12. Will Elite get only $15 million for ELI-200? What percentage of the royalties does Elite get? What exactly will the royalties consist of? What will the royalty be on the net product sales??
13. Did Epic ever settle with Purdue?
14. Does Epic have right of first refusal on future opioid ART drugs that are approved or is ELI-200 a one shot deal with plans
to bring in bigger game?
15. Does Epic have plans to ramp up sales and marketing departments in anticipation of marketing ELI-200 or future ART drugs?
16. What are the chances of an Epic and Elite merger? What would a reverse merger do to the PPS?
17. What's the current status of Mikah and the relation between Mikah/Epic as well as any possible conflict of interest that relation can cause to Elite?
18. Will there be a new valuation/assessment?
19. Will there be any Pie Charts to show shareholders the increase in shares?
20. We seem to have been "flying under the radar" for quite awhile now. Does Nasrat plan on presenting at more conferences (Rodman and Renshaw and others) to promote awareness and interest in the company now that we are in the last stretch for ELI 200?
21. Since EPIC is going to be marketing its own ER ADT OXY and Elite's IR ADT OXY at the same time, which ADT will Epic be using.....Will it be a hard turtle shell version like Purdue/Actavis has agreed upon.......OR is EPIC going to be using a version of Elite's ADT?
22. What are the scenarios/circumstances that would engage Elite to pursue up listing to the Nasdaq or anything comparable?
23. The annual shareholders meeting- when? There has been speculation that it's "pushed-back" timing may coincide with some expected big news/results/announcements?
Elite Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss 1st Quarter 2016 Financial Results on August 11, 2015
Financials for 1st Quarter Ended June 31, 2015 Will be Released on August 10, 2015
NORTHVALE, N.J., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that its first quarter financial results will be released on Monday, August 10, 2015. Following the announcement, Elite's management will host a live conference call and webcast on Tuesday, August 11th at 11:00 a.m. Eastern Daylight Time to review the company's financial and operating results and provide a general business update. Company executives will conduct a question and answer session following their remarks.
Conference Call Information
Date: Tuesday, August 11, 2015
Time: 11:00 a.m. EDT
Webcast (live and archive) & Audio Replay: http://ir.elitepharma.com/events_presentations
Dial-in numbers: 1-800-346-7359 (domestic)
1-973-528-0008 (international)
Conference number: 98840
Got questions for ELTP's Management?... Then get cracking and add them to the CC Q&A list!:
**** Elite Pharmaceuticals Conference Call Questions ****
Those participating in ELTP’s Conference Call Q&A session are limited to asking one question following ELTP management’s opening statements. To make the most of this Q&A opportunity, suggest that we come up with a list to share of top questions to ask:
(Copy/paste the latest posted list and add your question(s) at the end of the list)
1. Any plans for ELI-154?
2. Updates on ELI-201 and ELI-202?
3. Update on ELI-202 BE?
4. Any generics moving up the ladder to commercialization?
5. Elite had an agreement with Epic for 8 drugs where Elite gets a 15% profit split. Elite is no longer proceeding with the last 7 drugs. However, the first and only drug has been filed with the FDA for 3 1/2 years now and we haven't heard anything. Do you have any updates on this?
6. Are there any numbers yet on the sales of Isradpin?
7. Status update on the arbitration of Phentermine with Precision Dose?
8. Given Elite's generic NDA ART line takes less time and money to bring to market than Elite's once daily Eli 216 product, what are the current plans for this product? How likely is it to partner a combo Eli 201 and 216 together? How quickly are you planning to move forward with this product since there is no other once daily abuse resistant product on the market?
9. What is the up to date information on the Public Float and Shares Outstanding for ELTP?
10. Given Nasrat's experience working at Alpharma and Actavis... Does he think Elite's patents are different enough from Purdue not to move toward legal avenues? If not, does Nasrat believe royalties fees would be the end result for Elite?
11. How does Elite's ADT compare to other ADT products that purport to detour swalling a handful of pills? What would it take to get Elite to attach "similar" ADT. How does Elite's microtablet technology improve on Elite's existing ADT? What is the microtablet technology worth once Elite begins to market its ADT opioids?
12. Will Elite get only $15 million for ELI-200? What percentage of the royalties does Elite get? What exactly will the royalties consist of? What will the royalty be on the net product sales??
13. Did Epic ever settle with Purdue?
14. Does Epic have right of first refusal on future opioid ART drugs that are approved or is ELI-200 a one shot deal with plans
to bring in bigger game?
15. Does Epic have plans to ramp up sales and marketing departments in anticipation of marketing ELI-200 or future ART drugs?
16. What are the chances of an Epic and Elite merger? What would a reverse merger do to the PPS?
17. What's the current status of Mikah and the relation between Mikah/Epic as well as any possible conflict of interest that relation can cause to Elite?
18. Will there be a new valuation/assessment?
19. Will there be any Pie Charts to show shareholders the increase in shares?
20. We seem to have been "flying under the radar" for quite awhile now. Does Nasrat plan on presenting at more conferences (Rodman and Renshaw and others) to promote awareness and interest in the company now that we are in the last stretch for ELI 200?
21. Since EPIC is going to be marketing its own ER ADT OXY and Elite's IR ADT OXY at the same time, which ADT will Epic be using.....Will it be a hard turtle shell version like Purdue/Actavis has agreed upon.......OR is EPIC going to be using a version of Elite's ADT?
22. What are the scenarios/circumstances that would engage Elite to pursue up listing to the Nasdaq or anything comparable?
23. The annual shareholders meeting- when? There has been speculation that it's "pushed-back" timing may coincide with some expected big news/results/announcements?
So did e-Trade:
Aug 03, 2015 08:00:00 (ET)
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial
**** Elite Pharmaceuticals Conference Call Questions ****
Those participating in ELTP’s Conference Call Q&A session are limited to asking one question following ELTP management’s opening statements. To make the most of this Q&A opportunity, suggest that we come up with a list to share of top questions to ask:
(Copy/paste the latest posted list and add your question(s) at the end of the list)
1. Any plans for ELI-154?
2. Updates on ELI-201 and ELI-202?
3. Update on ELI-202 BE?
4. Any generics moving up the ladder to commercialization?
5. Elite had an agreement with Epic for 8 drugs where Elite gets a 15% profit split. Elite is no longer proceeding with the last 7 drugs. However, the first and only drug has been filed with the FDA for 3 1/2 years now and we haven't heard anything. Do you have any updates on this?
6. Are there any numbers yet on the sales of Isradpin?
7. Status update on the arbitration of Phentermine with Precision Dose?
8. Given Elite's generic NDA ART line takes less time and money to bring to market than Elite's once daily Eli 216 product, what are the current plans for this product? How likely is it to partner a combo Eli 201 and 216 together? How quickly are you planning to move forward with this product since there is no other once daily abuse resistant product on the market?
9. What is the up to date information on the Public Float and Shares Outstanding for ELTP?
10. Given Nasrat's experience working at Alpharma and Actavis... Does he think Elite's patents are different enough from Purdue not to move toward legal avenues? If not, does Nasrat believe royalties fees would be the end result for Elite?
11. How does Elite's ADT compare to other ADT products that purport to detour swalling a handful of pills? What would it take to get Elite to attach "similar" ADT. How does Elite's microtablet technology improve on Elite's existing ADT? What is the microtablet technology worth once Elite begins to market its ADT opioids?
12. Will Elite get only $15 million for ELI-200? What percentage of the royalties does Elite get? What exactly will the royalties consist of? What will the royalty be on the net product sales??
13. Did Epic ever settle with Purdue?
14. Does Epic have right of first refusal on future opioid ART drugs that are approved or is ELI-200 a one shot deal with plans
to bring in bigger game?
15. Does Epic have plans to ramp up sales and marketing departments in anticipation of marketing ELI-200 or future ART drugs?
16. What are the chances of an Epic and Elite merger? What would a reverse merger do to the PPS?
17. What's the current status of Mikah and the relation between Mikah/Epic as well as any possible conflict of interest that relation can cause to Elite?
18. Will there be a new valuation/assessment?
19. Will there be any Pie Charts to show shareholders the increase in shares?
20. We seem to have been "flying under the radar" for quite awhile now. Does Nasrat plan on presenting at more conferences (Rodman and Renshaw and others) to promote awareness and interest in the company now that we are in the last stretch for ELI 200?
21. Since EPIC is going to be marketing its own ER ADT OXY and Elite's IR ADT OXY at the same time, which ADT will Epic be using.....Will it be a hard turtle shell version like Purdue/Actavis has agreed upon.......OR is EPIC going to be using a version of Elite's ADT?
22. What are the scenarios/circumstances that would engage Elite to pursue up listing to the Nasdaq or anything comparable?
23. The annual shareholders meeting- when? There has been speculation that it's "pushed-back" timing may coincide with some expected big news/results/announcements?
Fellow ELTP Investors,
Since indications are that ELTP could hold its Conference Call next week, I'd like to once again facilitate the collection of shareholder input for the Q&A session with ELTP management.
For those who have not participated in ELTP's Q&A session before, I'll repeat the purpose/intent of putting together the question list. Due to time constraints, callers who participate in the Q&A session are limited to asking one question. We’ve got some very knowledgeable shareholders here on iHub who are well versed in the pharmaceutical sector and can provide excellent questions. But they may not be available for the Conference Call or, if they do partake, will be allotted only one question to ask. That’s where the rest of us come in. By referring to the Conference Call Question List, we can collectively get most, if not all, of the questions asked.
I will kickoff the list with leftover questions from June’s Conference Call that were either not asked or are still relevant for updates.
Please note that my role is NOT to censor or editorialize submitted questions. If you have an opinion on what should or should not be asked at the Q&A session, then please voice it via a public post on this board. Of course, it's ultimately each callers' prerogative as to what they choose to ask with their allotted question.
With that being said, the Conference Call Question list will follow.
MJ
Perhaps Nasrat Hakim will be presenting at the 17th Annual Rodman & Renshaw Global Investment Conference....